<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313910</url>
  </required_header>
  <id_info>
    <org_study_id>225193</org_study_id>
    <secondary_id>201118675</secondary_id>
    <nct_id>NCT01313910</nct_id>
  </id_info>
  <brief_title>CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements</brief_title>
  <official_title>CCRC: A Pilot Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Proliant Health &amp; Biologicals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if ImmunoLin® will reduce the frequency of bowel movements
      and gastrointestinal (GI) symptoms in HIV volunteers with persistent GI symptoms. The study
      will also examine the effect of ImmunoLin® on the bacteria in the gut and the immune system
      in gut tissue as well as in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Bowel Movements Per Day</measure>
    <time_frame>8 weeks (56 days)</time_frame>
    <description>self-reported bowel movement in diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Pro-inflammatory Bacterial Orders</measure>
    <time_frame>8 weeks</time_frame>
    <description>16S rDNA sequencing for Bacteroidetes/Firmicutes ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Gut Permeability</measure>
    <time_frame>8 weeks</time_frame>
    <description>five-hour disaccharide absorption test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Immune Activation</measure>
    <time_frame>8 weeks</time_frame>
    <description>CD8+ T-cells with an activated phenotype (HLA-DR/CD38+ coexpression)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duodenal Immune Reconstitution</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes in duodenal lamina propria CD3+/CD4+ density by immunohistochemistry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>ImmunoLin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8-week treatment course</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Immunolin®</intervention_name>
    <description>Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks</description>
    <arm_group_label>ImmunoLin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GI complaints consisting of at least 2 loose or watery stools per day or marked
             abdominal bloating that adversely effects activities of daily living (ADLs) or common
             social functioning for greater than 6 months, even though the symptomatology may wax
             and wane over that time period.

          -  Subjects should have had routine testing to exclude enteric pathogens.

          -  Subjects should have made an effort to identify food intolerance, especially lactose
             intolerance.

          -  Symptoms should be believed to be independent of ART or other medications known to
             have the potential to cause similar GI complaints; either because the symptoms predate
             initiation of the medications or shifts between different options for ART has had no
             appreciable effect on symptoms.

          -  Over the previous 6 months, alcohol use should be characterized as occasional with
             less than 1.5 ounces per day being the maximum estimated use (&lt;2 beers or glasses of
             wine or 1 drink of hard liquor).

          -  Subjects will be greater than 18 years of age.

          -  Plasma HIV load should be suppressed to less than 400 cp/mL for at least four months,
             but there is no restriction on peripheral CD4+ T-cell count. Blips of &lt;1000 cp/mL are
             allowed, provided that these are not associated with medication interruptions and that
             the pVL is undetectable before and after the observed blip.

          -  Subjects are willing to maintain a food and GI-symptom diary while receiving the
             ImmunoLin® supplement.

          -  Subjects should be willing to attempt to maintain a stable regimen of ART for the
             duration of the study unless indicated for patient safety.

          -  Subjects should be free of antibiotic use for at least 3-weeks prior to study entry
             except for chronic antibiotics used for prophylaxis according to SOC in HIV
             management. Usage of antibiotics during the course of the study will be assessed on a
             case by case basis by the study team.

          -  Subjects must be free of conditions which require chronic therapy that are known to
             alter the gut flora. Steroid use must be limited to intermittent topical preparations
             only which includes inhaled or dermatologic routes of application.

        Exclusion Criteria:

          -  known unrelated causes for GI abnormalities.

          -  abnormal coagulation parameters (PT&gt;1.2 ULN)

          -  thrombocytopenia (platelet count &lt;50,000 within 6 weeks)

          -  contra-indications to upper endoscopy or conscious sedation

          -  anemia (&gt; grade 1 [appendix D])

          -  aspirin, ibuprofen, warfarin or other agents that interfere with the coagulation
             cascade are prohibited within 1 week of endoscopy.

          -  positive pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Asmuth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis Int Med: ID</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCD CTSC Clinical Research Center (CCRC)</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Asmuth DM, Ma ZM, Albanese A, Sandler NG, Devaraj S, Knight TH, Flynn NM, Yotter T, Garcia JC, Tsuchida E, Wu TT, Douek DC, Miller CJ. Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS. 2013 Sep 10;27(14):2207-17. doi: 10.1097/QAD.0b013e328362e54c.</citation>
    <PMID>23660579</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <results_first_submitted>September 15, 2013</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2017</results_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>HIV Enteropathy</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with diagnosis of HIV enteropathy are eligible for enrollment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ImmunoLin®</title>
          <description>2.5 grams twice daily for eight weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ImmunoLin®</title>
          <description>8-week treatment course</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Bowel Movements Per Day</title>
        <description>self-reported bowel movement in diary</description>
        <time_frame>8 weeks (56 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ImmunoLin®</title>
            <description>8-week treatment course</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bowel Movements Per Day</title>
          <description>self-reported bowel movement in diary</description>
          <units>bowel movements/day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline stool frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week-8 stool frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Wilcoxin-rank test used to determine decrease in bowel movements/day after 8 weeks of intervention</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Pro-inflammatory Bacterial Orders</title>
        <description>16S rDNA sequencing for Bacteroidetes/Firmicutes ratio</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ImmunoLin®</title>
            <description>8-week treatment course</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Pro-inflammatory Bacterial Orders</title>
          <description>16S rDNA sequencing for Bacteroidetes/Firmicutes ratio</description>
          <units>ratio of Bacteroidetes/Firmicutes %</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline Bacteroidetes/Firmicutes ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0.20" upper_limit="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week-8 Bacteroidetes/Firmicutes ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" lower_limit="0.37" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Gut Permeability</title>
        <description>five-hour disaccharide absorption test</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ImmunoLin®</title>
            <description>8-week treatment course</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Gut Permeability</title>
          <description>five-hour disaccharide absorption test</description>
          <units>percentage absorption</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline permiability ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".024" lower_limit="0" upper_limit=".048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week-8 permeability ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032" lower_limit="0" upper_limit="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Immune Activation</title>
        <description>CD8+ T-cells with an activated phenotype (HLA-DR/CD38+ coexpression)</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ImmunoLin®</title>
            <description>8-week treatment course</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Immune Activation</title>
          <description>CD8+ T-cells with an activated phenotype (HLA-DR/CD38+ coexpression)</description>
          <units>% CD8/HLA-DR/CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline CD8+ activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="17.8" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week-8 CD8+ activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="17.8" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duodenal Immune Reconstitution</title>
        <description>changes in duodenal lamina propria CD3+/CD4+ density by immunohistochemistry</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ImmunoLin®</title>
            <description>8-week treatment course</description>
          </group>
        </group_list>
        <measure>
          <title>Duodenal Immune Reconstitution</title>
          <description>changes in duodenal lamina propria CD3+/CD4+ density by immunohistochemistry</description>
          <units>CD3+/CD4+ per mm^2 lamina propria</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline duodenal CD3+/CD4+ cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" lower_limit="66" upper_limit="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 week duodenal CD3+/CD4+ cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322" lower_limit="228" upper_limit="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ImmunoLin®</title>
          <description>8-week treatment course</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>pilot open label study with eight subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Asmuth, MD</name_or_title>
      <organization>UCaliforniaDavis</organization>
      <phone>9167348695</phone>
      <email>david.asmuth@ucdmc.ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

